rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2007-3-13
|
pubmed:abstractText |
Molecular modeling studies led to the rational discovery of N(1)-arylsulfonyl-1,3-dihydro-2H-benzimidazol-2-one as a novel template for the design of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are active against wild-type and mutant strains of HIV-1. It is worth noting that compound 3 proved to have antiretroviral activity similar to that of efavirenz and greater than that of nevirapine, two of the three NNRTIs currently available in antiretroviral therapy.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0960-894X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1956-60
|
pubmed:meshHeading |
pubmed-meshheading:17276064-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:17276064-Anti-Retroviral Agents,
pubmed-meshheading:17276064-Benzoxazines,
pubmed-meshheading:17276064-Cell Line,
pubmed-meshheading:17276064-Chemistry, Pharmaceutical,
pubmed-meshheading:17276064-Drug Design,
pubmed-meshheading:17276064-Enzyme Inhibitors,
pubmed-meshheading:17276064-HIV-1,
pubmed-meshheading:17276064-Humans,
pubmed-meshheading:17276064-Inhibitory Concentration 50,
pubmed-meshheading:17276064-Models, Molecular,
pubmed-meshheading:17276064-Molecular Conformation,
pubmed-meshheading:17276064-Mutation,
pubmed-meshheading:17276064-Nevirapine,
pubmed-meshheading:17276064-Reverse Transcriptase Inhibitors
|
pubmed:year |
2007
|
pubmed:articleTitle |
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
|
pubmed:affiliation |
Dipartimento Farmaco-Chimico, Università di Messina, Viale Annunziata, 98168 Messina, Italy. barreca@pharma.unime.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|